Keywords: USA, FDA, Alexion, Solaris, Johnson & Johnson, Remicade, Uremic sydrome, aHUS, Ulcerative colitis, Children

FDA approves Alexion’s Soliris for rare pediatric blood disorder and J&J’s Remicade for children with UC

Article | 25 September 2011

Print This

The US Food and Drug Administration on Friday approved Alexion Pharmaceuticals’ (Nasdaq: ALXN) Soliris (eculizumab) to treat patients with ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in